<DOC>
	<DOCNO>NCT02382653</DOCNO>
	<brief_summary>100 patient Breakthrough pain allocate receive either oral prioxicam ( OP ) ( n=50 ) sublingual fentanyl ( SLF ) ( n=50 ) . Patients divide randomly two equal group : oral prioxicam ( OP ) Group sublingual fentanyl citrate ( SLF ) Group , comprise 50 patient . Pain intensity level 0-10 visual analog scale ( VAS ) , patient instruct use 10-cm visual analog scale ( VAS ) ( 0 = pain 10 = worst possible pain ) . frequency Breakthrough pain throughout day , onset relief ( 0-5 , 6-10 , 11-15 , 16 min ) , time require dose titration , patient satisfaction adverse effect assess 3 , 7 , 15 , 30 day start treatment .</brief_summary>
	<brief_title>Oral Piroxicam Versus Buccal Fentanyl Breakthrough Pain</brief_title>
	<detailed_description>In prospective , longitudinal , controlled-study , 100 patient Breakthrough pain allocate receive either oral prioxicam ( OP ) ( n=50 ) sublingual fentanyl ( SLF ) ( n=50 ) . Patients divide randomly two equal group : oral prioxicam ( OP ) Group sublingual fentanyl citrate ( SLF ) Group , comprise 30 patient . Eligible participant adult age 18 suffer Background pain cancer pain whose cancer pain treat strong opioids breakthrough pain meet criterion describe Portenoy . ( 5 ) ( stable analgesia previous 48 h , control background pain previous 24 h , transient exacerbation pain previous 24 h ) . The term strong opioid refers medicine classify step three World Health Organization ( WHO ) analgesic ladder . In Egypt strong opioids available include fentanyl , morphine hydromorphone . Exclusion criterion less than18 year old , non-controlled basal pain , hospitalize patient , cognitive disturbance , patient contraindication NSAIDS gastric ulcer , impaired renal function , cerebrovascular accident , Coronary artery bypass graft , Uncontrolled hypertension , patient coagulation anomalies hepatic disease patient previous history allergy NSAID . Randomization perform random number use sealed envelope without sex stratification . Sealed envelope indicate group assignment . An independent anesthesiologist , participate study data collection , read number contain envelope make group assignment . Patients blindly randomize two group ; process inclusion study go request number patient reach . Pain intensity level 0-10 visual analog scale ( VAS ) , patient instruct use 10-cm visual analog scale ( VAS ) ( 0 = pain 10 = worst possible pain ) . frequency Breakthrough pain throughout day , onset relief ( 0-5 , 6-10 , 11-15 , 16 min ) , time require dose titration , patient satisfaction adverse effect assess 3 , 7 , 15 , 30 day start treatment . The primary outcome degree breakthrough pain score use VAS two group . The secondary outcome measure analgesic requirement , patient satisfaction , identification undesirable effect may associate use drug patient breakthrough pain group . All adverse event relate surgery regional anesthetic technique record .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Piroxicam</mesh_term>
	<criteria>Eligible participant : adult age 18 suffer Background pain cancer pain whose cancer pain treat strong opioids breakthrough pain meet criterion describe Portenoy . Exclusion criterion : less than18 year old , noncontrolled basal pain , hospitalize patient , cognitive disturbance , patient contraindication NSAIDS : gastric ulcer , impaired renal function , cerebrovascular accident , coronary artery bypass graft , uncontrolled hypertension , patient coagulation anomalies hepatic disease patient previous history allergy NSAID .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>